January's FDA oncology approvals offer new treatment options for breast cancer, mantle cell lymphoma, and other malignancies.

Palliative care is often associated with a patient entering end of life treatment and giving up on their treatment, but that ...

This video segment discusses strategies to help CAR-T therapy patients maintain quality of life, focusing on lifestyle ...

The 2-year benefit of bevacizumab in colorectal cancer may explain why survival benefits are seen in studies with two-year, ...

Phone calls to follow up with patients with locally advanced esophageal squamous cell carcinoma while at home may reduce AEs ...

Several new treatment options for patients with breast cancer have emerged over the last few years, including more oral ...

Key opinion leaders examine approaches to managing skin-related side effects, such as rash, in patients on EGFR inhibitors, ...

BC, CNM, RNFA, spoke about the oncology nurse’s and APP’s roles in managing chemotherapy-induced peripheral neuropathy in ...

T-DXd has received FDA approval for the treatment of unresectable or metastatic HR+, HER2-low/-ultralow breast cancer in ...

The addition of trastuzumab and pertuzumab to chemotherapy was associated with increased toxicity in patients with ...

Findings from this survey also demonstrated that 23% of providers were comfortable with interpreting biomarker testing ...

This video segment explores the challenges of managing neurologic toxicities, including ICANS, in CAR-T therapy, highlighting ...